Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.

Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection.

BACKGROUND: The potential therapeutic benefits of CD3 monoclonal antibodies, such as OKT3, have been limited by their immunogenicity and their propensity to activate a severe cytokine release syndrome. This has constrained the clinical use of OKT3 to the treatment of acute rejection episodes of orga...

Full description

Bibliographic Details
Main Authors:	Friend, P, Hale, G, Chatenoud, L, Rebello, P, Bradley, J, Thiru, S, Phillips, J, Waldmann, H
Format:	Journal article
Language:	English
Published:	1999

Similar Items

The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.
by: Routledge, E, et al.
Published: (1995)

Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study
by: Lawson, C, et al.
Published: (2005)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
by: Rebello, P, et al.
Published: (1999)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
by: Friend, P, et al.
Published: (1991)

Engineering aglycosylated antibody variants with immune effector functions
by: Sazinsky, Stephen L. (Stephen Lael)
Published: (2011)

Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.
by: Friend, P, et al.
Published: (1987)

CD4 and CD8 monoclonal antibody therapy in the dog: strategies to induce tolerance to renal allografts.
by: Watson, C, et al.
Published: (1995)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
by: Friend, P, et al.
Published: (1988)

Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.
by: Friend, P, et al.
Published: (1995)

Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies.
by: Watson, C, et al.
Published: (1994)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
by: Clatworthy, MR, et al.
Published: (2009)

Transgenic plants of Nicotiana tabacum L. express aglycosylated monoclonal antibody with antitumor activity
by: Meilyn Rodríguez, et al.

Delayed allograft rejection in primates treated with anti-IL-2 receptor monoclonal antibody Campath-6.
by: Tighe, H, et al.
Published: (1988)

Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
by: Abbs, I, et al.
Published: (1994)

CD4 and CD8 monoclonal antibody therapy in canine renal allografts.
by: Watson, C, et al.
Published: (1994)

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes.
by: Hale, G, et al.
Published: (2010)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
by: Clatworthy, MR, et al.
Published: (2007)

Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
by: Hale, G, et al.
Published: (1998)

Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance.
by: Kuhn, C, et al.
Published: (2011)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
by: Hale, G, et al.
Published: (1986)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
by: Watson, C, et al.
Published: (2004)

CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
by: Watson, C, et al.
Published: (1993)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
by: Hale, G, et al.
Published: (1994)

CD4 monoclonal antibodies in the preclinical dog renal allograft model.
by: Watson, C, et al.
Published: (1993)

Subclinical rejection and borderline changes in early protocol biopsies following renal transplantation
by: Roberts, I, et al.
Published: (2003)

A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection
by: Macklin, P, et al.
Published: (2017)

The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon.
by: Friend, P, et al.
Published: (1987)

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
by: Hale, G, et al.
Published: (2000)

Predictors of graft outcome in renal transplant recipients with antibody-mediated rejection
by: Ergün Parmaksız, et al.
Published: (2021-02-01)

The role of CD4+ T-cell subsets in determining transplantation rejection or tolerance.
by: Zelenika, D, et al.
Published: (2001)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
by: Friend, P, et al.
Published: (1989)

Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation.
by: Roberts, I, et al.
Published: (2004)

Effect of graft perfusion with two CD45 monoclonal antibodies on incidence of kidney allograft rejection.
by: Brewer, Y, et al.
Published: (1989)

The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation.
by: Friend, P, et al.
Published: (1991)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
by: Watson, C, et al.
Published: (2005)

Late acute antibody mediated rejection after nine years of renal transplantation
by: Halim Medhat, et al.
Published: (2010-01-01)

Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study.
by: Morgan, A, et al.
Published: (1997)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
by: Lockwood, C, et al.
Published: (1993)

Protection against hyperacute rejection by transgenic expression of human decay accelerating factor after prolonged cold ischaemia in pig-to-primate renal xenotransplantation
by: Masroor, S, et al.
Published: (2000)